about   CII home   shop   checkout
 
April 24, 2019
11 am to 12 pm EDT
Schedule conflict?
Register and you'll receive a copy of the recording!
 
Why industry leaders are choosing the Simoa technology for Phase I – IV Clinical Studies  

Webinar Description:

Join Dr. Maribeth Raines, Vice President of Laboratory Services at Pacific Biomarkers and Kevin Hrusovsky, CEO and Chairman of Quanterix as they discuss how the next generation Simoa SP-X Imaging and Analysis System and CorPlex Assays are helping accelerate clinical trials and drug development programs. . Dr Raines will share specific examples of how these single- and multiplex assays provide CROs like Pacific Biomarkers with the resources to support Phase I-IV clinical trials more effectively.

Learning Objectives:

  • Understand how top CRO labs are utilizing the Simoa SP-X Imaging and Analysis System
  • Highlight select Simoa assays (single and multiplex) and how they benefit clinical trials
  • Understand the role of novel biomarker detection technologies in clinical trial endpoint considerations
  • Learn about specific examples of utilizing novel biomarker detection technologies to advance the understanding of drug efficacy, toxicity, dosage response, and other parameters

Speakers:

Dr. Maribeth Raines
Vice President of Laboratory Services
Pacific Biomarkers

Dr. Maribeth Raines joined Pacific Biomarkers in 2012 and serves as its Vice President of Laboratory Services. In her current position, Dr. Raines manages the laboratory operations including all technology transfers at Pacific Biomarkers. In her current role, Dr. Raines is responsible for providing scientific leadership and technical support to the Company’s laboratory operations and R&D programs. Dr. Raines is biochemist with a broad-based background in a variety of areas but especially in oncology, inflammation, and virology as well as in biomarker discovery, development and commercialization. Prior to joining Pacific Biomarkers, Dr. Raines served as Director of Scientific Affairs for Quest Diagnostics Clinical Trials, where she helped establish biomarker, anatomic pathology, and flow cytometry testing for drug development. She was also responsible for building strategic alliances in emerging markets, standardizing processes, and harmonizing test results among multiple laboratories for global biomarker deployment. Prior to that position, she served as Director of R&D at both Nichols Institute Diagnostics and BioSource International (now known as Life Technologies). In addition, she has served on the faculty at UCLA School of Medicine in the Radiation Oncology Division. Dr. Raines earned a B.S. degree in Biology from St. Francis University, and a Ph.D. in Biochemistry from Michigan State University.

Kevin Hrusovsky
President, Chairman and CEO
Quanterix Corp; Founder, Powering Precision Health

With over 25 years of experience in the life sciences industry, Kevin has dedicated his career to transforming the practices of medicine and health. As the founder of the Powering Precision Health Summit, Kevin spearheaded the creation of an executive think tank of researchers, scientists, physicians and innovators to highlight the latest research on new biomarkers that are transforming healthcare into personalized medicine. With a proven track record for commercializing disruptive technologies, Kevin joined Quanterix in 2014 and currently serves as the President, Chairman and Chief Executive Officer. Kevin also serves on the Board of Directors of several companies shaping the future of precision health, including Quanterix, BioreclamationIVT, 908 Devices and Solect Energy. He also serves on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston. Prior to Quanterix, Kevin served as CEO of Caliper Life Sciences, turning the company into one of the fastest growing biotech businesses in the region, leading to a $600-million acquisition by PerkinElmer Life Sciences & Technology. Following the acquisition, Kevin served as President of PerkinElmer. Earlier, he was CEO of Zymark Corporation, President of FMC Pharmaceuticals and International Agricultural Products and held numerous management positions at DuPont. He formerly served on the boards of SeraCare, Caliper Life Sciences, Xenogen – XGEN and Alliant Medical Technology. He is the 2013 Entrepreneur of the Year from Ohio State University and holds an Honorary Doctorate degree from Framingham State University for contributions in life sciences and personal medicine. Kevin holds a B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University.

 

Cost: No Cost!